Table 1.
Patient demographics and characteristics
| Nivolumab | Nivolumab plus relatlimab | |
|---|---|---|
| n (female, male) | 30 (15, 15) | 30 (13, 17) |
| Age in years, median (range) | 64 (43–77) | 67 (43–81) |
| ECOG PS (0, 1) | 28, 2 | 28, 2 |
| Histology | ||
| Adenocarcinoma | 13 | 15 |
| Squamous cell carcinoma | 10 | 9 |
| Adenosquamous carcinoma | 2 | 2 |
| Other | 5 | 4 |
| Clinical stage (UICC eighth edition) | ||
| IB | 8 | 10 |
| IIA | 5 | 1 |
| IIB | 13 | 16 |
| IIIA | 4 | 3 |
| PD-L1 status (TPS) | ||
| <1% | 6 | 8 |
| 1–49% | 14 | 15 |
| ≥50% | 10 | 7 |
| Smoking status | ||
| Current | 5 | 16 |
| Former | 22 | 13 |
| Nonsmoker | 3 | 1 |
| Occupational exposure | ||
| Yes | 2 | 3 |
| No | 27 | 26 |
| Unknown | 1 | 1 |
ECOG PS, Eastern Cooperative Oncology Group performance score; TPS, tumor proportional score.